Menu
Recruiting NCT06435195

Clinical Characteristics and Analysis of Pituitary Complex and Rare Diseases

Observational Pituitary Diseases

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Surgical Removal, Biopsy.
Who it may be relevant to
Registry conditions: Pituitary Diseases. Basic parameters: No limits · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The goal of this observational study is to systematically describe the clinical characteristics and outcomes of patients with pituitary complex and rare diseases at Peking Union Medical College Hospital. The main questions it aims to answer are: * What are the influencing factors and rates of remission? * What are the comorbidities associated with these diseases? * What are the perioperative events, radiological findings, and pathological features? Researchers will compare different patient groups to see if there are significant differences in these outcomes. Participants will: * Undergo detailed clinical evaluations. * Provide medical history and data for analysis. * Participate in follow-up assessments to monitor disease progression and treatment outcomes.

Detailed description

The study aims to provide a comprehensive analysis of pituitary complex and rare diseases at Peking Union Medical College Hospital. By leveraging a large cohort, the research will explore various clinical characteristics and outcomes. Specifically, the study will examine influencing factors and rates of remission, the presence of comorbidities, and perioperative events. Additionally, it will evaluate radiological findings and pathological features to better understand these conditions. Through this detailed investigation, the study seeks to enhance knowledge and inform clinical practice regarding the management and prognosis of pituitary complex and rare diseases.

Interventions

  • Procedure Surgical Removal
    Resection of pituitary pathologies.
  • Procedure Biopsy
    Taking a small tissue or liquid sample from the pituitary pathologies and the affected area for examination and diagnosis

Primary outcome measures

  • Remission [Time frame: Postoperative one week and extends to the latest follow-up, estimated at up to 3 years]
Secondary outcome measures (2)
  • Disease Comorbidities [Time frame: From patient admission to an evaluation period extending up to the latest follow-up, estimately up to 3 years]
  • Postoperative complications [Time frame: Postoperative one week and extends to the latest follow-up, estimated at up to 3 years]

Eligibility criteria

Inclusion criteria

  • Diagnosed with rare sellar diseases including but not limited to pituitary adenomas (such as Thyrotropin-secreting pituitary adenomas, GH-secreting adenomas), craniopharyngiomas, Rathke's cleft cysts, sellar region germ cell tumors, cavernous sinus syndrome, and other diseases
  • Detailed medical history, including clinical symptoms, treatment plans and follow-up outcomes

Exclusion criteria

  • Incomplete medical records, especially missing key imaging diagnostic results
  • Patients with coexisting primary central nervous system diseases unrelated to sellar region diseases (such as severe traumatic brain injury)
  • Patients whose sellar region pathological diagnosis was changed or overturned during the follow-up period

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Peking Union Medical College Hospital — Beijing

Identifiers

NCT: NCT06435195 · K5112

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗